DelveInsight's, “Oncolytic Virus Cancer Therapy Pipeline Insight, 2025,” report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline ...

Analysts now project the global oncology drug market could surpass US$900 billion in revenue by 2034. Precedence Research ...

Oncolytic Virus Drugs Uptake and Pipeline Development Activities . The Oncolytic Virus drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted ...

Oncolytic virus therapy is not a new discovery, but it may now be positioned as the next major breakthrough in cancer treatment following the ... Over the last twenty years of development, ...

FDA designates MB-101 CAR T-cell therapy for glioblastoma, highlighting its potential in treating aggressive brain tumors ...

Eric Groen will serve as legal chief, compliance chief and head of business development for Genelux Corp., which is led by a ...

Paris, France, June 4th, 2025. Oncovita, a biotechnology company developing innovative virus-based immunotherapies for cancer treatment, today announced that the U.S. Food and Drug Administration ...

Shares of Mustang Bio MBIO skyrocketed 180.7% on Monday after the company announced that the FDA granted Orphan Drug ...

One-in-six patients treated with the modified virus as part of a clinical trial saw their tumors disappear completely.

Mustang Bio shares are trading sharply higher Monday afternoon. The FDA granted Orphan Drug Designation to its cell therapy, ...

UP Oncolytics, Inc. was founded in 2022 by Dr. Richard Rovin and Dr. Parvez Akhtar.The company is developing oncolytic virus treatments for rare and resistant cancers like glioblastoma.